The FDA extended the duration of use of Nexplanon for pregnancy prevention in women of reproductive potential for up to 5 years.
JERSEY CITY, N.J., January 17, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced ...
Organon & Co. OGN recently announced that the FDA has approved a supplemental New Drug Application, extending the duration of ...
Organon (OGN) has received FDA approval to expand the label of its birth control implant Nexplanon from its current three years to five years. Read more here.
(RTTNews) - Organon (OGN) announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON (etonogestrel implant). NEXPLANON is ...
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results